灰区淋巴瘤的临床病理共识研究:具有介于弥漫大B细胞淋巴瘤与经典型霍奇金淋巴瘤之间特征的病变
该共识研究对北美15个学术中心诊断的68例灰区淋巴瘤(GZL)进行中心病理复核,仅26例(38%)确认为GZL。确认与重新分类病例的纵隔受累比例(69% vs 41%,P=0.038)及>1处结外病灶比例(0% vs 25%,P=0.019)存在差异;低白蛋白血症为不良预后因素,一线CHOP±R与改善3年PFS相关。
要点
- 中心病理复核后仅38%(26/68)的GZL诊断被确认,42例被重新分类为其他淋巴瘤。
- 确认GZL较重新分类病例更常见纵隔受累(69% vs 41%),更少>1处结外病灶(0% vs 25%)。
- 低白蛋白血症与较差3年PFS相关(12% vs 64%),一线CHOP±R与较好3年PFS相关(70% vs 20%)。
核心结论
- GZL的准确诊断仍具挑战性,需要改进治疗策略。
- 中心病理复核对GZL诊断共识至关重要。
- 低白蛋白血症为GZL不良预后因素,一线CHOP±R与改善PFS相关。
研究设计与样本
- 多中心共识研究,纳入北美15个学术中心诊断的68例GZL病例,经中心病理复核达成共识。
- 中位随访44个月。
主要发现
- 68例中仅26例(38%)经中心复核确认为GZL,42例被重新分类:结节硬化型经典型霍奇金淋巴瘤27例(含10例结节硬化2级)、淋巴细胞为主型霍奇金淋巴瘤4例、弥漫大B细胞淋巴瘤4例、EBV阳性弥漫大B细胞淋巴瘤3例、原发纵隔大B细胞淋巴瘤2例、富于淋巴细胞经典型霍奇金淋巴瘤及B细胞淋巴瘤非特指型各1例。
- GZL确认病例免疫组化:CD20+ 83%、PAX5+ 100%、BCL6+ 20%、MUM1+ 100%、CD30+ 92%、EBV+ 4%。
- 确认GZL vs 重新分类病例:纵隔受累69% vs 41%(P=0.038),>1处结外病灶0% vs 25%(P=0.019)。
- 确认GZL vs 重新分类病例:3年PFS 39% vs 58%(P=0.19),3年OS 95% vs 85%(P=0.15)。
- 结节硬化2级重新分类患者PFS与确认GZL相似。
关键数值与推荐
- GZL共识诊断中形态学关键(如肿瘤细胞丰富程度)。
- 免疫组化显示普遍B细胞来源、常见CD30表达、EBV罕见阳性。
- 低白蛋白血症为不良预后因素(3年PFS 12% vs 64%,P=0.01)。
- 一线CHOP±R与改善3年PFS相关(70% vs 20%,P=0.03)。
临床怎么用
- GZL诊断应经中心病理复核以达成共识。
- 低白蛋白血症可用于GZL预后评估。
- 一线CHOP±R可能与改善PFS相关。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Gray zone lymphoma (GZL) is described as sharing features with classical Hodgkin lymphoma (cHL) and diffuse large B-cell lymphoma (DLBCL). However, there remains complexity in establishing diagnosis, delineating prognosis, and determining optimum therapy. Sixty-eight cases diagnosed as GZL across 15 North American academic centers were evaluated by central pathology review to achieve consensus. Of these, only 26 (38%) were confirmed as GZL. Morphology was critical to GZL consensus diagnosis (eg, tumor cell richness); immunohistochemistry showed universal B-cell derivation, frequent CD30 expression, and rare Epstein-Barr virus (EBV) positivity (CD20+, 83%; PAX5+, 100%; BCL6+, 20%; MUM1+, 100%; CD30+, 92%; EBV+, 4%). Forty-two cases were reclassified: nodular sclerosis (NS) cHL, n = 27 (including n = 10 NS grade 2); lymphocyte predominant HL, n = 4; DLBCL, n = 4; EBV+ DLBCL, n = 3; primary mediastinal large BCL n = 2; lymphocyte-rich cHL and BCL-not otherwise specified, n = 1 each. GZL consensus-confirmed vs reclassified cases, respectively, more often had mediastinal disease (69% vs 41%; P = .038) and less likely more than 1 extranodal site (0% vs 25%; P = .019). With a 44-month median follow-up, 3-year progression-free survival (PFS) and overall survival for patients with confirmed GZL were 39% and 95%, respectively, vs 58% and 85%, respectively, for reclassified cases (P = .19 and P = .15, respectively). Interestingly, NS grade 2 reclassified patients had similar PFS as GZL consensus-confirmed cases. For prognostication of GZL cases, hypoalbuminemia was a negative factor (3-year PFS, 12% vs 64%; P = .01), whereas frontline cyclophosphamide, doxorubicin, vincristine, and prednisone ± rituximab (CHOP±R) was associated with improved 3-year PFS (70% vs 20%; P = .03); both factors remained significant on multivariate analysis. Altogether, accurate diagnosis of GZL remains challenging, and improved therapeutic strategies are needed.
引用
- Pilichowska M, Pittaluga S, Ferry JA, et al. Clinicopathologic consensus study of gray zone lymphoma with features intermediate between DLBCL and classical HL. Blood Adv. 2017. PMID: 29296913. doi:10.1182/bloodadvances.2017009472
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。